Home » Stocks » Ligand Pharmaceuticals

Ligand Pharmaceuticals Inc. (LGND)

Stock Price: $117.93 USD -1.15 (-0.97%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
After-hours: $117.95 +0.02 (0.02%) Aug 4, 7:09 PM

Stock Price Chart

Key Info

Market Cap 1.89B
Revenue (ttm) 109.96M
Net Income (ttm) -61.17M
Shares Out 16.05M
EPS (ttm) -3.40
PE Ratio n/a
Forward PE 33.33
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 4, 2020
Last Price $117.93
Previous Close $119.08
Change ($) -1.15
Change (%) -0.97%
Day's Open 122.32
Day's Range 116.75 - 122.97
Day's Volume 402,827
52-Week Range 57.24 - 127.80

More Stats

Market Cap 1.89B
Enterprise Value 1.57B
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 16.05M
Float 15.38M
EPS (basic) -2.39
EPS (diluted) -3.40
FCF / Share -3.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 9.00M
Short Ratio 27.87
Short % of Float 78.91%
Beta 1.64
PE Ratio n/a
Forward PE 33.33
P/FCF Ratio n/a
PS Ratio 17.21
PB Ratio 2.84
Revenue 109.96M
Operating Income -11.00M
Net Income -61.17M
Free Cash Flow -60.23M
Net Cash 318.03M
Net Cash / Share 19.82
Gross Margin 48.22%
Operating Margin -10.00%
Profit Margin -55.60%
FCF Margin -54.77%
ROA -0.52%
ROE -7.02%
ROIC -2.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (8)

Buy 6
Overweight 0
Hold 2
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$184.00*
(56.02% upside)
Low
145
Current: $117.93
High
229
Target: 184.00
*Average 12-month price target from 6 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue12025114110971.9164.5448.9731.3930.0423.54
Revenue Growth-52.17%78.21%29.48%51.53%11.43%31.78%56.02%4.5%27.61%-
Gross Profit10924513610366.1155.4043.2427.7925.1323.54
Operating Income80716468.0843.8927.3319.6314.940.19-2.58-31.01
Net Income62914312.56-1.6423012.0211.42-0.539.72-10.37
Shares Outstanding19.0021.1621.0320.8319.7920.4220.3119.8519.6619.61
Earnings Per Share31.855.960.53-0.0810.830.560.55-0.030.49-0.53
EPS Growth434.4%1024.53%--1833.93%1.82%----
Operating Cash Flow-29.3419488.5760.7341.7320.5720.690.16-1.17-27.07
Capital Expenditures-2.55-10.894.90-19.55-4.12-1.01-3.95-0.580.45-0.73
Free Cash Flow-31.8918393.4741.1937.6019.5616.74-0.41-0.72-27.80
Cash & Equivalents1,07079620614420516917.3215.1518.3824.04
Total Debt6496362252132021969.1128.2830.29-
Net Cash / Debt421160-18.99-68.663.02-27.318.21-13.13-11.9024.04
Assets1,4951,26167160250325810510412175.56
Liabilities72870025223122623455.1077.7810472.06
Book Value76756140034123726.3249.6126.498.19-4.85
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Ligand Pharmaceuticals Inc.
Country United States
Employees 115
CEO John L. Higgins

Stock Information

Ticker Symbol LGND
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: LGND
IPO Date November 18, 1992

Description

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; and Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations. It also offers bazedoxifene for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Minnebro for the treatment of hypertension; and Bryxta for non-small cell lung cancer. The company's partners programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney, and other diseases. It is also developing a small molecule glucagon receptor antagonist for the treatment of Type 2 diabetes mellitus. In addition, the company is involved in the sale of Captisol materials. Ligand Pharmaceuticals Incorporated was founded in 1987 and is headquartered in San Diego, California.